Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1994; 23:82-91
© 1994 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Remme, W.
Right arrow Articles by de Leeuw, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Remme, W.
Right arrow Articles by de Leeuw, P.

Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans

WJ Remme, DA Kruyssen, MP Look, M Bootsma, and PW de Leeuw

Zuiderziekenhuis and Sticares Cardiovascular Research Foundation, Rotterdam, The Netherlands.

OBJECTIVES. The purpose of this study was to assess the effect of different degrees of ischemia on circulating and cardiac neurohormones and vasotone. BACKGROUND. Neuroendocrine activation and subsequent systemic vasoconstriction may complicate ischemia. Whether this relates to severity of ischemia and subsequent cardiac dysfunction, and whether neurohormonal balance in the ischemic area changes, is unknown. METHODS. Fifty-six normotensive patients with coronary artery disease were evaluated during incremental atrial pacing. On the basis of ST segment changes, patients were classified in a nonischemic (n = 11) or ischemic group (n = 45), the latter patients were subsequently classified as lactate (n = 28) or nonlactate (n = 17) producing, to identify neurohormonal changes in the effluent of the ischemic myocardium. RESULTS. Angina occurred in 55%, 82% and 82% of patients in the nonischemic, lactate- and nonlactate-producing groups, respectively. Baseline hemodynamic variables and neurohormones were comparable in all groups, as were heart rate, rate-pressure product and coronary hemodynamic variables during pacing. In lactate producers, contractility did not improve, relaxation deteriorated, left ventricular filling pressure increased and cardiac output decreased during pacing, indicating more severe ischemia compared with that in nonlactate producers. Neurohormones did not change in the nonischemic group. In contrast, arterial and coronary venous catecholamines increased significantly more in lactate producers than in nonlactate producers (arterial norepinephrine by 68% vs. 36%, respectively). Moreover, arterial angiotensin II increased in lactate producers from a baseline mean +/- SEM of 6.8 +/- 0.9 to 9.7 +/- 1.6 pmol/liter (p < 0.05), accompanied by a sustained 23% increase in systemic resistance and arterial pressures. In lactate producers, baseline net cardiac norepinephrine release changed to net uptake during pacing (-0.05 +/- 0.02 vs. 0.06 +/- 0.05 nmol/min, p < 0.05). Epinephrine uptake increased in all patients with ischemia, albeit more in lactate producers. CONCLUSIONS. Circulating catecholamines and renin-angiotensin levels are activated, and systemic vasotone is increased in relation to the degree of ischemia. Cardiac epinephrine uptake increases, whereas net baseline norepinephrine release from the ischemic myocardium changes to net uptake. Modulation of this neurohormonal activation may provide an alternative mode to limit ischemia.


This article has been cited by other articles:


Home page
J CARDIOVASC PHARMACOL THERHome page
S. H. Hohnloser
Ventricular Arrhythmias: Antiadrenergic Therapy for the Patient with Coronary Artery Disease
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S23 - S31.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
W.J. Remme
Reconsider the management of all coronary artery disease patients: Importance of the EUROPA trial
Eur. Heart J. Suppl., July 1, 2003; 5(suppl_E): E23 - E30.
[Abstract] [PDF]


Home page
JNMHome page
S. Simula, E. Vanninen, L. Viitanen, A. Kareinen, S. Lehto, P. Pajunen, M. Syvanne, J. Kuikka, M. Laakso, and J. Hartikainen
Cardiac Adrenergic Innervation Is Affected in Asymptomatic Subjects with Very Early Stage of Coronary Artery Disease
J. Nucl. Med., January 1, 2002; 43(1): 1 - 7.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A.F.M Van Den Heuvel, D.J Van Veldhuisen, G.L Bartels, M Van Der Ent, and W.J Remme
Differential anti-ischaemic effects of muscarinic receptor blockade in patients with obstructive coronary artery disease. Impaired vs normal left ventricular function
Eur. Heart J., December 1, 1999; 20(23): 1717 - 1723.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
C. A. Schneider, E. Voth, D. Moka, F. M. Baer, J. Melin, A. Bol, R. Wagner, H. Schicha, E. Erdmann, and U. Sechtem
Improvement of myocardial blood flow to ischemic regions by angiotensin- converting enzyme inhibition with quinaprilat IV: A study using [15O] water dobutamine stress positron emission tomography
J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1005 - 1011.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
F Bode, U Wiegand, W Raasch, G Richardt, and J Potratz
Differential effects of defibrillation on systemic and cardiac sympathetic activity
Heart, June 1, 1998; 79(6): 560 - 567.
[Abstract] [Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement